[Product Releases]
|
|
|
|
|
[Blog]
|
|
Most recent post
|
[News]
|
|
Can we trust docking results? Sept 2010 IBM Systems and Technology Group releases a white paper with eHiTS and Cell
Oct 2008
EPA's ToxCastTM project will use SimBioSys' eHiTS as docking engine
Nov, 2007
|
[Events]
|
| 243rd ACS
Mar 25-29, 2012 San Diego, CA
see >> more
|
|
|
|
|
Company Info
SimBioSys® is a recognized leader in the field of rational drug discovery software. Providing a wide range of software solutions, the company is focused on the development of scientific tools to facilitate the drug discovery process. It retains a constant focus on the innovation of algorithms to provide improved throughput and accuracy in the fields of flexible docking, virtual screening and de-novo structure design. SimBioSys is also a pioneer in the field of computer-aided retrosynthetic analysis where it supports chemists through the challenges of organic synthesis. With attention to detail, ease-of-use and improved productivity, SimBioSys has built a strong reputation of delivering state-of-the-art scientific solutions to biotechnology and pharmaceutical companies.
Background
SimBioSys Inc. was incorporated in 1996 as a side venture fom the
Institute for Computer Appliactions in Molecular Sciences (ICAMS) at
the University of Leeds, UK.
Since becoming incorporated, the first 4 years were devoted to the
development of technology infrastructure MoDeST (Molecular Design Software Toolkit). The next years were
focused on application development and today SimBioSys is
ready to market new products such as eHiTS, LASSO, ARChem etc. all developed on its molecular modelling platform: MoDeST
Company Profile
SimBioSys develops 3-dimensional molecular modelling software for the
pharmaceutical drug discovery industry.
The products and services are developed with the following goals in
mind:
- acceleration of the drug discovery process
- increasing the speed and accuracy of drug R&D
- increasing the quality of research decisions
The Company's Vision
SimBioSys envisions being a leader in providing the highest quality and
performance interactive visual design software for the biomolecular
sciences.
The company's aim revolves around its mission statement: Reality3 - to be realistic in all three
dimensions:
- fully interactive real-time
software
- using realistic
scientific simulations
- packaged together to provide the most realistic visualization possible.
|
|
|